Aethlon medical receives ethics committee approval for hemopurifier® cancer trial

Aethlon medical granted full ethics approval from the human research ethics committee at central adelaide local health network for a safety, feasibility, and dose finding study of its hemopurifier® in cancer patients with solid tumors not responding to anti-pd-1 antibodies san diego , june 18, 2024 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on june, 13, 2024, the human research ethics committee (hrec) of the central adelaide local health network (calhn) granted full ethics approval for aethlon's safety, feasibility and dose-finding clinical trial of the hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-pd-1 monotherapy treatment, such as keytruda® (pembrolizumab) or opdivo® (nivolumab) (aemd-2022-06 hemopurifier study). the approval is valid for three years, until june 13, 2027.
AEMD Ratings Summary
AEMD Quant Ranking